Overcoming T cell exhaustion in infection and cancer

Trends in Immunology

Volumn 36, Issue 4, 2015, Pages 265-276

  Pauken, Kristen E ^a   Wherry, E John ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; Chronic infection; Immunotherapy; PD 1; PD L1; T cell exhaustion

Indexed keywords

ANTIBODY; ANTIRETROVIRUS AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

BLADDER CANCER; CANCER IMMUNOTHERAPY; CELL HETEROGENEITY; CELL POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; KIDNEY CARCINOMA; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; HEPATITIS; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIGENS, CD274; CHRONIC DISEASE; HEPATITIS; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84926528302     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.02.008     Document Type: Review

References (133)

1. Zajac A.J., et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 1998, 188:2205-2213.
2. Gallimore A., et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 1998, 187:1383-1393.
3. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
4. Goepfert P.A., et al. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J. Virol. 2000, 74:10249-10255.
5. Kostense S., et al. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur. J. Immunol. 2001, 31:677-686.
6. Shankar P., et al. Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood 2000, 96:3094-3101.
7. Gruener N.H., et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J. Virol. 2001, 75:5550-5558.
8. Lechner F., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 2000, 191:1499-1512.
9. Reignat S., et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J. Exp. Med. 2002, 195:1089-1101.
10. Lee P.P., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 1999, 5:677-685.
11. Barber D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
12. Iwai Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12293-12297.
13. Hirano F., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005, 65:1089-1096.
14. Sharma P., et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 2011, 11:805-812.
15. Mellman I.G., et al. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
16. Page D.B., et al. Immune modulation in cancer with antibodies. Annu. Rev. Med. 2014, 65:185-202.
17. Schreiber R.D., et al. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
18. Schietinger A., Greenberg P.D. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014, 35:51-60.
19. Kim P.S., Ahmed R. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 2010, 22:223-230.
20. Callahan M.K., Wolchok J.D. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J. Leukoc. Biol. 2013, 94:41-53.
21. Hamid O., et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
22. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
23. Brahmer J.R., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28:3167-3175.
24. Ohaegbulam K.C., et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol. Med. 2015, 21:24-33.
25. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
26. Lipson E.J., et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res. 2013, 19:462-468.
27. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
28. Herbst R.S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
29. Powles T., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
30. Topalian S.L., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 2014, 32:1020-1030.
31. Robert C., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372:320-330.
32. Ansell S.M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015, 372:311-319.
33. Wherry E.J., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
34. Blackburn S.D., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37.
35. Paley M.A., et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012, 338:1220-1225.
36. Johnston R.J., et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014, 26:923-937.
37. Keir M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
38. Fife B.T., Pauken K.E. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. N. Y. Acad. Sci. 2011, 1217:45-59.
39. Pauken K.E., et al. PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes. Diabetes 2013, 62:2859-2869.
40. Schietinger A., et al. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 2012, 335:723-727.
41. Duraiswamy J., et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J. Immunol. 2011, 186:4200-4212.
42. Wherry E.J., et al. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 2003, 77:4911-4927.
43. Jin X., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999, 189:991-998.
44. Schmitz J.E., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
45. Blattman J.N., et al. Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection. J. Virol. 2009, 83:4386-4394.
46. Jamieson B.D., et al. Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses. J. Immunol. 2003, 171:5372-5379.
47. Prakash M.D., et al. Granzyme B promotes cytotoxic lymphocyte transmigration via basement membrane remodeling. Immunity 2014, 41:960-972.
48. Surh C.D., Sprent J. Homeostasis of naive and memory T cells. Immunity 2008, 29:848-862.
49. Wherry E.J., et al. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16004-16009.
50. Shin H., et al. Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J. Exp. Med. 2007, 204:941-949.
51. Obar J.J., et al. Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J. Virol. 2006, 80:8303-8315.
52. Alter G., et al. Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection. J. Immunol. 2003, 171:477-488.
53. Oxenius A., et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13747-13752.
54. Utzschneider D.T., et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat. Immunol. 2013, 14:603-610.
55. Angelosanto J.M., et al. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J. Virol. 2012, 86:8161-8170.
56. Schwartz R.H. T cell anergy. Annu. Rev. Immunol. 2003, 21:305-334.
57. Doering T.A., et al. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 2012, 37:1130-1144.
58. Crawford A., et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 2014, 40:289-302.
59. Blackburn S.D., et al. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15016-15021.
60. Buggert M., et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. 2014, 10:e1004251.
61. Kaech S.M., Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 2012, 12:749-761.
62. Paley M.A., et al. Technical advance: fluorescent reporter reveals insights into eomesodermin biology in cytotoxic lymphocytes. J. Leukoc. Biol. 2013, 93:307-315.
63. Intlekofer A.M., et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 2005, 6:1236-1244.
64. Zhou X., et al. Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity 2010, 33:229-240.
65. Banerjee A., et al. Cutting edge: the transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J. Immunol. 2010, 185:4988-4992.
66. Intlekofer A.M., et al. Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells. J. Exp. Med. 2007, 204:2015-2021.
67. Mullen A.C., et al. Master transcription factors determine cell-type-specific responses to TGF-beta signaling. Cell 2011, 147:565-576.
68. Trompouki E., et al. Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell 2011, 147:577-589.
69. Curran M.A., et al. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J. Exp. Med. 2013, 210:743-755.
70. Fahey L.M., et al. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J. Exp. Med. 2011, 208:987-999.
71. Brooks D.G., et al. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J. Virol. 2005, 79:10514-10527.
72. Fuller M.J., Zajac A.J. Ablation of CD8 and CD4 T cell responses by high viral loads. J. Immunol. 2003, 170:477-486.
73. Oxenius A., et al. Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. Immunity 1998, 9:449-457.
74. Matloubian M., et al. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 1994, 68:8056-8063.
75. Schenkel J.M., et al. T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 2014, 346:98-101.
76. Curiel T.J., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9:562-567.
77. Fourcade J., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010, 207:2175-2186.
78. Baitsch L., et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J. Clin. Invest. 2011, 121:2350-2360.
79. Riches J.C., et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013, 121:1612-1621.
80. Zenz T., Exhausting T. cells in CLL. Blood 2013, 121:1485-1486.
81. Gros A., et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 2014, 124:2246-2259.
82. Ahmadzadeh M., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
83. Mumprecht S., et al. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Bloiod 2009, 114:1528-1536.
84. Fourcade J., et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J. Immunol. 2009, 182:5240-5249.
85. Radoja S., et al. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol. 2001, 167:5042-5051.
86. Matsuzaki J., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7875-7880.
87. Sfanos K.S., et al. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009, 69:1694-1703.
88. Muenst S., et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat. 2013, 139:667-676.
89. Zhang Y., et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell. Mol. Immunol. 2010, 7:389-395.
90. Spranger S., et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 2013, 5:200ra116.
91. Tumeh P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
92. Savage P.A., et al. Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol. Rev. 2014, 259:245-258.
93. Jin H.T., et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14733-14738.
94. McMahan R.H., et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 2010, 120:4546-4557.
95. Nakamoto N., et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 2009, 5:e1000313.
96. Topalian S.L., et al. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 2012, 24:207-212.
97. Wilson E.B., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
98. Teijaro J.R., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
99. Yi J.S., et al. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009, 324:1572-1576.
100. Frohlich A., et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009, 324:1576-1580.
101. Elsaesser H., et al. IL-21 is required to control chronic viral infection. Science 2009, 324:1569-1572.
102. Brooks D.G., et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 2006, 12:1301-1309.
103. Kao C., et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 2011, 12:663-671.
104. Staron M.M., et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity 2014, 41:802-814.
105. Shin H., et al. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 2009, 31:309-320.
106. Oestreich K.J., et al. NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 2008, 181:4832-4839.
107. Yokosuka T., et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 2012, 209:1201-1217.
108. Chemnitz J.M., et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 2004, 173:945-954.
109. Riley J.L. PD-1 signaling in primary T cells. Immunol. Rev. 2009, 229:114-125.
110. Sheppard K.A., et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004, 574:37-41.
111. Parry R.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 2005, 25:9543-9553.
112. Patsoukis N., et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal. 2012, 5:ra46.
113. Quigley M., et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med. 2010, 16:1147-1151.
114. Fife B.T., et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 2009, 10:1185-1192.
115. Honda T., et al. Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity 2014, 40:235-247.
116. Zinselmeyer B.H., et al. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J. Exp. Med. 2013, 210:757-774.
117. Iwai Y.S., et al. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 2005, 17:133-144.
118. Strome S.E., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003, 63:6501-6505.
119. Blank C., et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004, 64:1140-1145.
120. Gubin M.M., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
121. Twyman-Saint Victor C., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, (in press).
122. Mueller S.N., et al. PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J. Clin. Invest. 2010, 120:2508-2515.
123. Yadav M., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515:572-576.
124. Peng W., et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 2012, 72:5209-5218.
125. Pilon-Thomas S., et al. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 2010, 184:3442-3449.
126. Yang K., Fu L.W. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review. Crit. Rev. Oncol. Hematol. 2015, 93:277-292.
127. Xiao Y., et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J. Exp. Med. 2014, 211:943-959.
128. Martinez G.J., et al. The transcription factor NFAT promotes exhaustion of activated CD8 T cells. Immunity 2015, 42:265-278.
129. Pollizzi K.N., Powell J.D. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat. Rev. Immunol. 2014, 14:435-446.
130. Lu P., et al. Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J. Exp. Med. 2014, 211:515-527.
131. Youngblood B., et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 2011, 35:400-412.
132. Youngblood B., et al. Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J. Immunol. 2013, 191:540-544.
133. Zhang F., et al. Epigenetic manipulation restores functions of defective CD8(+) T cells from chronic viral infection. Mol. Ther. 2014, 22:1698-1706.